GSK plc
GSKHealthcareNASDAQDrug Manufacturers - General · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, GSK plc (GSK) is listed under Drug Manufacturers - General. The company carries a $101.68B market cap, placing it firmly in the large-cap category. It operates through Commercial Operations and Total R&D segments.
Market Cap
$101.68B
Beta
0.28
P/E (TTM)
16.01
P/E (Fwd)
10.31
EPS (TTM)
$3.17
EPS (Fwd)
$4.92
ROE
33.4%
ROA
10.0%
Cash
$3.11B
Total Debt
$18.29B
Free CF
$3.48B
52W Change
17.4%
Annual Financials
Cash vs Debt
Where GSK stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GSK finished 3.40% below its 150-day moving average ($51.20) and 4.30% below its 200-day moving average ($51.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GSK overbought or oversold?
At the October 20, 2026 close, GSK's RSI(14) was 50.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, GSK has $3.11B in cash with $18.29B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $3.48B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 33.4%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.0% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $29.32B to $32.67B.
The relatively low beta of 0.28 suggests GSK is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing GSK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.